JP2002020299A - Placenta-containing sublingual tablet - Google Patents
Placenta-containing sublingual tabletInfo
- Publication number
- JP2002020299A JP2002020299A JP2000202143A JP2000202143A JP2002020299A JP 2002020299 A JP2002020299 A JP 2002020299A JP 2000202143 A JP2000202143 A JP 2000202143A JP 2000202143 A JP2000202143 A JP 2000202143A JP 2002020299 A JP2002020299 A JP 2002020299A
- Authority
- JP
- Japan
- Prior art keywords
- placenta
- component
- sublingual tablet
- tablet
- gradually
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】この発明は、胎盤（プラセン
タ）が有する人体に対して有用な微量生理活性成分を、
体内に吸収するための錠剤に関するものである。TECHNICAL FIELD The present invention relates to a trace amount of a physiologically active ingredient useful for the human body of the placenta (placenta).
It relates to tablets for absorption into the body.
【０００２】[0002]
【従来の技術とその課題】胎盤（プラセンタ）とは人、
牛、羊、やぎなどの動物が妊娠中、胎児を包む膜と、子
宮とを結ぶところに位置する円盤状の臓器で出産と同時
に後産として体内に排出されるものである。胎盤は胎児
煮を子宮で育てる元になり、生命の誕生の基礎になるも
のである。2. Description of the Related Art Placenta (placenta) is a human,
During pregnancy, animals such as cows, sheep, and goats are discoid organs that connect the membrane surrounding the fetus to the uterus and are excreted into the body at the same time as childbirth. The placenta is the source of fetal boil in the womb and the basis for the birth of life.
【０００３】その為、美肌効果、精力増強、更年期障害
の治療、若返り、肝機能の改善、または近年、白血病の
骨髄に代わるものとして注目されているばかりでなく、
多くの有用成分を含んでいるものである。[0003] For this reason, not only has it gained attention as a replacement for the bone marrow of leukemia,
It contains many useful ingredients.
【０００４】このプラセンタの投与には、錠剤、カプセ
ル、顆粒等による経口投与、または注射が一般的であっ
たが、それぞれの投与方法には一長一短があった。[0004] Oral administration of tablets, capsules, granules, or the like, or injection is generally used to administer this placenta, but each administration method has advantages and disadvantages.
【０００５】即ち、経口投与では胎盤エキス中に存在す
る生理活性物質、各種活性ペプチド、核酸、酵素、ホル
モン様物質、各種活性成長因子などが胃酸で破壊され、
吸収されないため、薬理効果が充分でない、またはミネ
ラル、アミノ酸、ビタミンなどの吸収が遅く、即効性は
期待できないなどの欠点を有している。[0005] That is, in oral administration, physiologically active substances, various active peptides, nucleic acids, enzymes, hormone-like substances, various active growth factors, etc. present in the placenta extract are destroyed by stomach acid,
Since it is not absorbed, it has drawbacks such as insufficient pharmacological effect, or slow absorption of minerals, amino acids, vitamins, etc., so that immediate effect cannot be expected.
【０００６】また注射による投与方法は、上記の欠点は
解決できるけれども、いつでもどこでも簡単にプラセン
タの成分を摂取できないのみならず、注射による投与で
は急速に胎盤エキス中の活性物質が体内に入るため、一
時的に気分が悪くなるなどの副作用を伴うことがある。[0006] Although the above-mentioned drawbacks can be solved by the administration method by injection, not only the placenta component cannot be easily ingested anytime and anywhere, but also the active substance in the placenta extract rapidly enters the body by administration by injection. May be accompanied by side effects such as temporary feeling sick.
【０００７】この発明は、上記問題点に鑑みてなされた
ものであり、プラセンタの成分を胃酸によって破壊され
ることなく、かつ、徐々に人体に吸収させることができ
る錠剤を提供することを課題とする。[0007] The present invention has been made in view of the above problems, and has as its object to provide a tablet capable of gradually absorbing the placenta component into the human body without being destroyed by stomach acid. I do.
【０００８】[0008]
【課題を解決するための手段】上記の課題を解決するた
め、本発明は、口内で時間をかけて徐々に溶解する成分
からなる舌下錠に、プラセンタの成分を含有させたこと
を特徴とするプラセンタ含有舌下錠である。Means for Solving the Problems In order to solve the above-mentioned problems, the present invention is characterized in that a sublingual tablet comprising a component which gradually dissolves in the mouth over time contains a placenta component. Is a sublingual tablet containing placenta.
【０００９】本発明の特徴は胎盤中の有効成分を舌下吸
収させることにより、舌下の粘膜の微細な孔より胎盤中
の活性物質が序々に吸収されるため、穏やかにすばやく
その効果を得ることができるというものである。The feature of the present invention is that the active ingredient in the placenta is absorbed sublingually, whereby the active substance in the placenta is gradually absorbed from the fine pores of the mucous membrane under the tongue, so that the effect can be obtained gently and quickly. That you can do it.
【００１０】また舌下錠は出来るだけ、時間をかけ序々
に溶解するほうが、より効果があることも判明した。こ
こで言う舌下錠は一般的なトローチ剤のみならず、水あ
め、砂糖等からなるあめ玉、ドロップ等のものも含まれ
る。[0010] It has also been found that sublingual tablets are more effective when dissolved gradually over time as much as possible. The sublingual tablet referred to here includes not only general lozenges but also syrup made of water syrup, sugar and the like, and drops and the like.
【００１１】[0011]
【発明の実施の形態】以下この発明を実施例により説明
する。DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will be described below with reference to embodiments.
【００１２】実施例１ １０００ｇの胎盤をミンチ状に破砕し、２０００ｍｌの
３０％アルコール溶液で８０℃、３時間抽出する。Example 1 1000 g of placenta is minced and extracted with 2000 ml of a 30% alcohol solution at 80 ° C. for 3 hours.
【００１３】遠心分離機で上澄み液５００ｍｌを得たも
のを胎盤エキスとする。胎盤エキスに乳糖１００ｇを加
え減圧下、攪拌しながら加熱し水とアルコールを飛ば
し、プラセンタエキス末とする。[0013] A placenta extract is obtained by obtaining 500 ml of a supernatant liquid by a centrifuge. 100 g of lactose is added to the placenta extract, and the mixture is heated with stirring under reduced pressure to remove water and alcohol, thereby obtaining a placenta extract powder.
【００１４】プラセンタエキス末１０％に粉糖、アラビ
アゴム、ソルビトール等を混合し錠剤を成形しトローチ
錠を作り製品１とする。Powdered sugar, gum arabic, sorbitol and the like are mixed with 10% of placenta extract powder to form a tablet, and a troche is prepared to obtain product 1.
【００１５】実施例２ 水あめ７０部、砂糖３０部を混合し、減圧下加熱し濃縮
する。濃縮されたものを冷却し、成形直前にプラセンタ
エキス末３％を良く混合した後、成形し製品２とする。Example 2 70 parts of syrup and 30 parts of sugar are mixed, heated and concentrated under reduced pressure. The concentrated product is cooled, mixed with 3% of placenta extract powder immediately before molding, and molded to obtain product 2.
【００１６】比較例１ プラセンタエキス末１０％、粉糖、ソルビトール等を混
合し錠剤を成形し製品３とする。Comparative Example 1 A placenta extract powder (10%), powdered sugar, sorbitol and the like were mixed to form a tablet to obtain a product 3.
【００１７】比較例２ プラセンタエキス末１０％、粉糖、ソルビトール等を混
合し顆粒を作り製品４とする。Comparative Example 2 Placenta extract powder 10%, powdered sugar, sorbitol and the like are mixed to form granules, and the product 4 is obtained.
【００１８】テスト１ 各々５０名ずつ１００メートル、全力疾走した後、次の
テストを行った。製品１、２のものは人の口中の舌下に
錠剤を置き、１５分かけて序々に溶解させ、製品３、４
は水を飲むと同時に胃に流し込んだ。そのときの疲労回
復の状態を測定したところ表１に示す結果が得られた。Test 1 The following tests were conducted after sprinting 100 meters with 50 people each. For products 1 and 2, put the tablet under the tongue in the mouth of a person and dissolve gradually over 15 minutes.
Drank water and poured into the stomach at the same time. When the state of fatigue recovery at that time was measured, the results shown in Table 1 were obtained.
【００１９】[0019]
【表１】 [Table 1]
【００２０】テスト２ 次に血圧の測定を各々５名ずつ行い、テスト１と同様の
方法で製品を与え、１５分後それぞれについて測定した
結果は表２の通りであった。Test 2 Next, blood pressure was measured by 5 persons each, the products were given in the same manner as in Test 1, and after 15 minutes, the results of measurement were as shown in Table 2.
【００２１】[0021]
【表２】 [Table 2]
【００２２】テスト３ ５名について１日３錠、顆粒は同量、１週間服用した後
肝機能のＧＯＴの測定した結果は表３の通りであった。Test 3 Three tablets a day and the same amount of granules were taken for 5 people for one week, and the GOT of liver function was measured after taking the tablets for one week.
【００２３】[0023]
【表３】 [Table 3]
【００２４】テスト４ また、５名について１日３錠、顆粒は同量、１週間服用
した後肝機能のＧＰＴの測定した結果は表４の通りであ
った。Test 4 Also, the results of GPT measurement of liver function after taking three tablets a day and the same amount of granules for one week for five subjects were as shown in Table 4.
【００２５】[0025]
【表４】 [Table 4]
【００２６】以上のテストより、本発明に係る舌下錠と
しての製品１及び製品２の方が、通常の錠剤や顆粒であ
る製品３及び製品４よりも、プラセンタが有する各種効
果が有効に得られることが判った。From the above test, the products 1 and 2 as sublingual tablets according to the present invention can more effectively obtain the various effects of placenta than the products 3 and 4 which are ordinary tablets and granules. It turned out to be.
【００２７】[0027]
【発明の効果】以上のように、この発明によると、プラ
センタの成分を舌下吸収させることにより、プラセンタ
が有する各種生理活性成分を、胃酸で破壊することなく
速やかに体内に吸収させて効果を有効に得られる。As described above, according to the present invention, by absorbing the components of placenta under the tongue, various physiologically active components of the placenta can be quickly absorbed into the body without being destroyed by stomach acid. Effectively obtained.
【００２８】また、注射等をせずに得ることができ、更
に、舌下の粘膜の微細な孔よりプラセンタ成分が徐々に
体内に吸収させるため、注射を用いた場合の急激な投与
による一時的な不快感といった副作用が無いという利点
もある。Further, it can be obtained without injection and the like. Further, since the placenta component is gradually absorbed into the body through the fine pores of the mucous membrane under the tongue, the temporary administration due to rapid administration when using injection is required. There is also an advantage that there is no side effect such as discomfort.
─────────────────────────────────────────────────────
────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成１２年７月２１日（２０００．７．２
１）[Submission date] July 21, 2000 (2007.2)
1)
【手続補正１】[Procedure amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００２[Correction target item name] 0002
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【０００２】[0002]
【従来の技術とその課題】胎盤（プラセンタ）とは人、
牛、羊、やぎなどの動物が妊娠中、胎児を包む膜と、子
宮とを結ぶところに位置する円盤状の臓器で出産と同時
に後産として体外に排出されるものである。胎盤は胎児
を子宮で育てる元になり、生命の誕生の基礎になるもの
である。2. Description of the Related Art Placenta (placenta) is a human,
Cattle, sheep, animals pregnant such as goat, in which the membrane encasing the fetus, and is discharged to the body outside the afterbirth at birth with disk-shaped organs located at connecting the uterus. Placenta fetus
The one in which is the original to grow in the uterus, the underlying of the birth of life.
【手続補正２】[Procedure amendment 2]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００５[Correction target item name] 0005
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【０００５】即ち、経口投与では胎盤エキス中に存在す
る生理活性物質、各種活性ペプチド、核酸、酵素、ホル
モン様物質、各種活性成長因子などが胃酸で破壊され、
吸収されにくいため、薬理効果が充分でない、またはミ
ネラル、アミノ酸、ビタミンなどの吸収が遅く、即効性
は期待できないなどの欠点を有している。[0005] That is, in oral administration, physiologically active substances, various active peptides, nucleic acids, enzymes, hormone-like substances, various active growth factors, etc. present in the placenta extract are destroyed by stomach acid,
Since it is difficult to be absorbed, it has drawbacks such as insufficient pharmacological effect or slow absorption of minerals, amino acids, vitamins, etc., so that immediate effect cannot be expected.
【手続補正３】[Procedure amendment 3]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】０００６[Correction target item name] 0006
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【０００６】また注射による投与方法は、上記の欠点は
解決できるけれども、いつでもどこでも簡単にプラセン
タの成分を摂取できないのみならず、急速に胎盤エキス
中の活性物質が体内に入るため、一時的に気分が悪くな
るなどの副作用を伴うことがある。[0006] The method of administration by injection, although the above-mentioned drawbacks can be solved, not only can not be ingested at any time anywhere easily component of the placenta, rapidly for the active substance in the placenta extract is enters the body, temporarily May be accompanied by side effects such as feeling sick.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｐ 17/00 Ａ６１Ｐ 17/00 43/00 １０７ 43/00 １０７ Ｆターム(参考） 4B018 LB01 MD69 ME02 ME10 ME14 4C076 AA38 AA49 BB02 CC26 CC29 CC40 DD38A DD67A EE58 FF04 FF06 GG14 4C087 AA01 AA02 BB58 CA06 MA02 MA35 NA10 NA11 NA12 ZA75 ZA89 ZB22 ZB27 ZC02 ZC52──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (reference) A61P 17/00 A61P 17/00 43/00 107 43/00 107 F term (reference) 4B018 LB01 MD69 ME02 ME10 ME14 4C076 AA38 AA49 BB02 CC26 CC29 CC40 DD38A DD67A EE58 FF04 FF06 GG14 4C087 AA01 AA02 BB58 CA06 MA02 MA35 NA10 NA11 NA12 ZA75 ZA89 ZB22 ZB27 ZC02 ZC52
Claims (1)
からなる舌下錠に、プラセンタの成分を含有させたこと
を特徴とするプラセンタ含有舌下錠。1. A placenta-containing sublingual tablet characterized by comprising a placenta component in a sublingual tablet comprising a component which gradually dissolves in the mouth over time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000202143A JP2002020299A (en) | 2000-07-04 | 2000-07-04 | Placenta-containing sublingual tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000202143A JP2002020299A (en) | 2000-07-04 | 2000-07-04 | Placenta-containing sublingual tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002020299A true JP2002020299A (en) | 2002-01-23 |
Family
ID=18699711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000202143A Pending JP2002020299A (en) | 2000-07-04 | 2000-07-04 | Placenta-containing sublingual tablet |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002020299A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7338562B2 (en) | 2004-03-16 | 2008-03-04 | Fabio Alessio Romano Dionisi | Sugar cane juice clarification process |
| CN103141838A (en) * | 2013-03-10 | 2013-06-12 | 吉林省中韩动物科学研究院 | Preparation method and application of female calcium supplementing product |
| JP2014506921A (en) * | 2011-02-28 | 2014-03-20 | チャ バイオ アンド ダイオステック カンパニー リミテッド | Placenta extract and method for producing the same |
| CN103750001A (en) * | 2013-12-20 | 2014-04-30 | 吉林市长白加林特产开发有限公司 | Formula and preparation method of instant type granule electuary made of wood-frog spawn |
| CN114712323A (en) * | 2022-05-18 | 2022-07-08 | 贵州奇源生物制品有限公司 | Human placenta tablet and preparation method thereof |
-
2000
- 2000-07-04 JP JP2000202143A patent/JP2002020299A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7338562B2 (en) | 2004-03-16 | 2008-03-04 | Fabio Alessio Romano Dionisi | Sugar cane juice clarification process |
| JP2014506921A (en) * | 2011-02-28 | 2014-03-20 | チャ バイオ アンド ダイオステック カンパニー リミテッド | Placenta extract and method for producing the same |
| CN103141838A (en) * | 2013-03-10 | 2013-06-12 | 吉林省中韩动物科学研究院 | Preparation method and application of female calcium supplementing product |
| CN103750001A (en) * | 2013-12-20 | 2014-04-30 | 吉林市长白加林特产开发有限公司 | Formula and preparation method of instant type granule electuary made of wood-frog spawn |
| CN114712323A (en) * | 2022-05-18 | 2022-07-08 | 贵州奇源生物制品有限公司 | Human placenta tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vimy et al. | Mercury from maternal “silver” tooth fillings in sheep and human breast milk: a source of neonatal exposure | |
| Catz et al. | Drugs and breast milk | |
| Abdelnaby et al. | Melatonin and CIDR improved the follicular and luteal haemodynamics, uterine and ovarian arteries vascular perfusion, ovarian hormones and nitric oxide in cyclic cows | |
| JP2004238365A (en) | Skin beautifying agent, and beauty and health food | |
| JP2002020299A (en) | Placenta-containing sublingual tablet | |
| JPH0543474A (en) | Herb preparation composition for ready administration | |
| Ingoldby et al. | Induction of parturition in sheep | |
| Romagnoli et al. | Prolonged interval between parturition of normal live pups in a bitch | |
| West | Liver function in dairy cows in late pregnancy and early lactation | |
| CN111655245A (en) | Method of increasing embryo implantation rate in female subjects with polycystic ovary syndrome | |
| CN101404998A (en) | Oral agent for promoting synthesis of tissue collagen | |
| Airaodion et al. | In vitro and in vivo evaluation of Ananas comosus fruit (pineapple) on abortion/miscarriage in wistar rats | |
| Ross | Prolactin—its effect on the secretion of woman’s milk | |
| JP2004203750A (en) | Superovulation inducer for cattle | |
| JPH0352818A (en) | Remedy for osteoporosis | |
| RU2377999C2 (en) | Method for production of biostimulant from cow placenta | |
| US5858966A (en) | Fetal growth | |
| JPH10276717A (en) | Production of food for making woman bosomy | |
| Ahirwar et al. | Drugs Used during Pregnancy and Lactation | |
| Burdan | Effects of prenatal exposure to combination of acetaminophen, isopropylantipyrine and caffeine on intrauterine development in rats | |
| JPS59501949A (en) | Contraceptive vaginal tablets and their manufacturing method | |
| Murray | Contributions to teratology: Undescribed malformation of the lower lip occurring in four members of one family | |
| Nasset et al. | Canine and human gastric digestion of proteins in vivo | |
| Olaleye | Effects of Diets Containing Seeds of Soybean (Glycine max) on Healing of Acetic Acid Induced Gastric Ulcers in Rats | |
| Milk | Mercury from Maternal" Silver" Tooth Fillings in Sheep and Human Breast Milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051129 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060323 |